Literature DB >> 26666361

Pharmacology: On the mode of action of mirabegron.

Karl-Erik Andersson1.   

Abstract

Mesh：

Year:  2015        PMID： 26666361     DOI： 10.1038/nrurol.2015.297

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.

Authors:  Victor W Nitti; Steven Rosenberg; David H Mitcheson; Weizhong He; Allam Fakhoury; Nancy E Martin
Journal:  J Urol       Date:  2013-05-30       Impact factor: 7.450

2.  Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction.

Authors:  J I Gillespie; C Rouget; S Palea; C Granato; C Korstanje
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-06-07       Impact factor: 3.000

Review 3.  Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.

Authors:  Gian Marco Rosa; Simone Ferrero; Victor W Nitti; Adrian Wagg; Tahir Saleem; Christopher R Chapple
Journal:  Eur Urol       Date:  2015-09-28       Impact factor: 20.096

4.  Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor.

Authors:  Gianluigi D' Agostino; Anna Maria Condino; Paolo Calvi
Journal:  Eur J Pharmacol       Date:  2015-04-08       Impact factor: 4.432

5.  Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.

Authors:  Yoshihisa Matsukawa; Shun Takai; Yasuhito Funahashi; Tokunori Yamamoto; Momokazu Gotoh
Journal:  Urology       Date:  2015-02-20       Impact factor: 2.649

6.  Evidence for predominant mediation of alpha1-adrenoceptor in the tonus of entire urethra of women.

Authors:  N Taki; T Taniguchi; K Okada; N Moriyama; I Muramatsu
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

7.  A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.

Authors:  Dudley Robinson; Linda Cardozo; Gerben Terpstra; John Bolodeoku
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

8.  The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women.

Authors:  André Reitz; Axel Haferkamp; Tatiana Kyburz; Peter A Knapp; Björn Wefer; Brigitte Schurch
Journal:  Eur Urol       Date:  2004-08       Impact factor: 20.096

9.  Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.

Authors:  Yasuhiko Igawa; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-21       Impact factor: 3.000

10.  Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.

Authors:  E C Alexandre; L R Kiguti; F B Calmasini; F H Silva; K P da Silva; R Ferreira; C A Ribeiro; F Z Mónica; A S Pupo; E Antunes
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739
  10 in total
  5 in total

Review 1.  Mirabegron: potential off target effects and uses beyond the bladder.

Authors:  Nodi Dehvari; Edilson Dantas da Silva Junior; Tore Bengtsson; Dana Sabine Hutchinson
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

Review 2.  On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder.

Authors:  Karl Erik Andersson
Journal:  Int Neurourol J       Date:  2017-03-24       Impact factor: 2.835

3.  Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence.

Authors:  Mete Özkidik; Alper Coşkun; Mehmet Kazim Asutay; Tuncer Bahçeci; Nurullah Hamidi
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

4.  Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors.

Authors:  Kai Sun; Di Wang; Gang Wu; Jian Ma; Tianqi Wang; Jitao Wu; Jipeng Wang
Journal:  Cancer Med       Date:  2021-09-21       Impact factor: 4.452

Review 5.  Recent advances in pharmacological management of urinary incontinence.

Authors:  Bronagh McDonnell; Lori Ann Birder
Journal:  F1000Res       Date:  2017-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.